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Chronic Obstructive Pulmonary 
Disease (COPD) is a preventable 
cause of morbidity and mortality 
that poses a significant public health 
burden.  The disease is character-
ized by progressively worsening air-
flow limitation and chronic airway 
i n f l am m a t i o n  w i t h  h y p e r -
responsiveness to noxious particles 
and gases.  The airflow limitation 
seen in COPD is caused by disease 
of the small airways and parenchy-
mal destruction ( obstructive bron-
chiolitis and emphysema, respectively).  The associated chronic inflammation can 
lead to structural changes with narrowing of the small airways, loss of lung elastic 
recoil, and diminished ability of the lungs to remain open during the expiratory 
phase.   Previously used terminology to describe COPD may have failed to include 
the hallmark of the diagnosis, airflow limitation.  The term emphysema refers to the 
destruction of gas exchanging surfaces of the lung, and is a pathological description 
of one characteristic of COPD.  Another term, chronic bronchitis, defined as cough 
with sputum production for at least 3 months in each of 2 consecutive years, may 
be associated with normal spirometry. 
 
Treatment options for COPD include both pharmacologic and non-pharmacologic 
varieties, typically added in a stepwise fashion with the goals of controlling symp-
toms, improving quality of life, and decreasing the frequency and severity of exacer-
bations.  The goal of this review is to provide a guide for treatment of stable COPD, 
and has been taken from the most recent Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) guidelines, last updated in April of 2011. 
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Severity classifications set forth by the GOLD guidelines are often used to assist with guiding thera-
py.  In stage I disease, short-acting bronchodilators alone are typically adequate, with long-acting be-
ta agonists (LABA) and inhaled corticosteroids (ICS) typically being added in a stepwise fashion in 
stage II disease.  Classification of disease severity by gold criteria is as follows: 
 
 
Smoking cessation 
In patients who smoke, cessation can influence progression of disease greater than any other inter-
vention.  Long-term quit rates as high as 25% have been reported with effective use of resources.  
Pharmacologic interventions to assist with cessation include nicotine replacement as well as multiple 
other pharmacologic therapies.  When compared to placebo, nicotine replacement products are 
more effective and increase long-term smoking abstinence rates.   Contraindications to this form of 
therapy include unstable coronary artery disease, untreated peptic ulcer disease, recent MI, and re-
cent stroke.  Medications available to assist with cessation include Varenicline, bupropion, and 
nortriptyline, all of which have shown an increase in long-term quit rates compared to placebo.  In 
addition, counseling by healthcare providers for as little as 3 minutes regarding need for cessation 
creates quit rates of 5-10%.  When all available modalities for cessation are combined quit rates 
have been shown to increase to 35% at one year. 
 
Pharmacologic Therapy for Stable COPD 
Again, the goal of therapy is to reduce symptoms, reduce the frequency and severity of exacerba-
tions, and improve quality of life.  Commonly used medications in the treatment of stable COPD 
include beta 2 agonists, anti-cholinergics, and inhaled corticosteroids in combination with long-acting 
beta agonists.  The choice of a medication regimen is typically tailored based on patient response to 
therapy and cost.  None of the available medications have shown to improve the long-term decline 
in lung function seen in COPD.  For a list of commonly used medications, see table 3.3 in the most 
recent edition of the GOLD guidelines. 
Bronchodilators: 
Bronchodilators increase the FEV1 by decreasing airway smooth muscle tone and can be given on 
an as-needed or scheduled basis.   Effective bronchodilation results in improved emptying of the 
lungs, reduction in hyperinflation, and increased exercise tolerance.  Medications included in this 
class include beta-2 agonists, anti-cholinergics, and methylxanthines.   Commonly used short-acting 
bronchodilators include albuterol, levalbuterol, and ipratropium bromide.  Single or combination 
therapy is acceptable, but combination therapy with a short-acting beta-2 agonist and anti-
cholinergic provides greater and more sustained improvements in FEV1 compared to either class 
alone. 
Methylxanthines provide modest bronchodilation, but their use is limited by interactions with other 
medications and potential toxicity.  Routine use of methyl-xanthines is not recommended unless   
Stage I Mild COPD FEV1/FVC<0.70 FEV1 ≥ 80% normal 
Stage II Moderate COPD FEV1/FVC<0.70 FEV1 50-79% normal 
Stage III Severe COPD FEV1/FVC<0.70 FEV1 30-49% normal 
Stage IV Very Severe COPD FEV1/FVC<0.70 
FEV1 <30% normal, or <50% 
normal with chronic respiratory 
failure present 
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other bronchodilators are not available or are unaffordable for long-term treatment. Long acting 
beta agonists (LABA), such as formoterol and salmeterol, improve FEV1, lung volumes, dyspnea, 
quality of life, and exacerbation rates.  Duration of action is 12 hours or more, although a long-
acting beta-agonist with duration of action lasting 24 hours, Indacaterol, has recently become availa-
ble. 
Tiotropium is a long-acting anti-cholinergic bronchodilator that has a duration of action > 24 hours.  
It has been shown to reduce exacerbations and related hospitalizations, improve symptoms, and 
also to improve the effectiveness of pulmonary rehabilitation. 
 
Corticosteroids, Inhaled: 
Inhaled corticosteroids (ICS) can improve symptoms, lung function, quality of life, and reduce the 
frequency of exacerbations if used regularly in patients with an FEV1 < 60% predicted.  ICS are rec-
ommended for patients with severe and very severe airflow limitation and for patients with frequent 
exacerbations that are not controlled by LABA.  There is no effect on long-term decline in FEV1 or 
mortality, but it should be noted that withdrawal from treatment with ICS may lead to exacerba-
tions of COPD. 
Combination therapy with ICS and LABA is more effective than either class alone, and has been 
shown to reduce exacerbations and improve lung function and health status in patients with moder-
ate to very severe COPD.  One large prospective clinical trial showed no statistically significant ef-
fect of combination therapy on mortality, but meta-analysis indicated that combination therapy may 
reduce mortality.  Combination of ICS/LABA with tiotropium has not been well studied, but has 
been shown to improve lung function and quality of life, and may lead to a reduction in the number 
of exacerbations. 
 
Corticosteroids, systemic: 
The numerous side effects associated with long-term treatment with corticosteroids limit their use 
clinically. Of particular importance is steroid-induced myopathy, which can lead to weakness, de-
creased functional ability, and respiratory failure.  Routine use is not recommended. 
 
Phosphodiesterase-4 Inhibitors: 
These reduce inflammation by inhibiting the breakdown of intracellular cyclic AMP.  Roflumilast is a 
once daily oral medication of this class.  It has no bronchodilator activity, but has been shown to 
improve FEV1 in patients treated with salmeterol or tiotropium.  Roflumilast has been shown to 
reduce exacerbations that require corticosteroids by 15-20% in patients with chronic bronchitis, 
severe to very severe COPD, and a history of previous exacerbations.  Use should be limited to 
this subset of patients. 
 
Other Pharmacologic Treatments 
Vaccines 
The influenza vaccine can reduce serious illness and even death in COPD patients.  Yearly vaccina-
tion is recommended.  Pneumococcal vaccination is suggested for patients 65 years and older and , 
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younger patients with comorbid conditions, and has also reduced the incidence of community-
acquired pneumonia in COPD patients < 65 years of age with an FEV1 < 40% predicted. 
 
Alpha-1 Antitrypsin Augmentation Therapy 
This therapy is reserved for young patients with severe hereditary alpha-1 antitrypsin deficiency and 
emphysema.  Therapy is only available in select countries and is very expensive. 
 
Antibiotics 
Older studies have shown both continuous prophylactic antibiotics and antibiotic prophylaxis during 
winter months have no benefit in reducing the frequency of exacerbations.   More recent studies 
have shown some beneficial effects of antibiotics on exacerbation rate, including a recent trial of daily 
azithromycin, but further studies are needed before this type of treatment can be recommended due 
to concern for antibiotic resistance. Hence at this time, antibiotics should be reserved for infection-
induced exacerbations and other bacterial infections. 
 
Mucolytic and Antioxidant Agents 
Use of these agents has been investigated in multiple studies with differing results.  The overall bene-
fits are small, and routine use is not recommended. 
 
Antitussives 
Inhibition of cough in COPD is not recommended as this is an important protective mechanism for 
mucus clearance.  Routine use of antitussives is not recommended. 
 
Vasodilators 
Pulmonary hypertension is believed to be associated with a worsened prognosis in COPD.  While it 
would seem beneficial to reduce right ventricular afterload and improve oxygen delivery to the tis-
sues, results of studies have been disappointing.  Nitric oxide has been shown to worsen gas ex-
change by altering hypoxic vasoconstriction, creating increased blood flow to poorly ventilated lung 
units.  This drug is contraindicated in stable COPD, and the use of endothelium-modulating agents as 
treatment for pulmonary hypertension in COPD patients is not recommended pending further stud-
ies. 
 
Narcotics 
In patients with very severe disease, dyspnea is effectively treated using oral or parenteral narcotics.  
Nebulized opiates may be effective, but definitive data is still lacking.  Serious side effects can occur, 
and patients must be made aware of potential consequences of overuse. 
Non-Pharmacologic Therapies 
Pulmonary Rehabilitation: 
Pulmonary rehabilitation focuses on problems that may not be addressed with normal medical man-
agement of COPD, including deconditioning, social isolation, depression, muscle wasting, and weight 
loss.  Goals of pulmonary rehab include reducing symptoms, improving quality of life, and increasing 
physical and emotional participation in activities of daily life.   Increases in peak workload, peak oxy-
gen consumption, and endurance have been well documented as a result of pulmonary rehabilitation. 
The minimum duration of an effective program is six weeks, and the benefits continue to increase  
Page 5 
with further increases in the duration of program. If a formal program is unavailable it is to advise 
graded increases in physical activity with a goal of 20 minutes per day.  Most programs include exer-
cise training, smoking cessation assistance, nutrition counseling, and education regarding COPD and 
medical therapy for the disease. 
 
Other Treatments 
Oxygen Therapy: 
Administration of oxygen therapy for > 15 hours per day in patients with severe resting hypoxemia 
has been shown to increase their survival.  Long-term oxygen therapy is indicated for those with: 
• A PaO2 at or below 55 mmHg or SaO2 at or below 88% confirmed on two occasions over a 
three week period.  This can be with or without hypercapnia. 
(Or) 
• A PaO2 between 55 and 60 mmHg, or SaO2 of 88% in the setting of pulmonary hyperten-
sion, peripheral edema suggesting congestive cardiac failure, or polycythemia (Hct > 55%). 
•  
Ventilatory Support: 
Non-invasive ventilation (NIV) is being used more frequently in patients with stable, very severe 
COPD.  There may be a survival benefit associated with NIV use, but quality of life remains unaffect-
ed.  In those patients with both COPD and obstructive sleep apnea there are benefits in both surviv-
al and hospital admission rates with use of NIV. 
 
Surgical Treatments 
Multiple surgical interventions exist as potential treatment for very severe COPD, including Lung 
Volume Reduction Surgery, Bronchoscopic Lung Volume Reduction, Lung Transplantation, and Bul-
lectomy.  All carry significant operative and post-operative risks, and are typically associated with a 
higher health care cost when compared to medical management of COPD.  Strict patient selection is 
required to optimize outcomes. 
 
Summary 
This review was intended to give general guidelines regarding medical management of stable COPD.  
The goal of therapy is to reduce symptoms, increase exercise tolerance, improve health status, re-
duce the frequency of exacerbations, prevent disease progression and reduce mortality.  These goals 
should be reached with the fewest possible side effects from medications, which is often difficult giv-
en the number of comorbidities seen in COPD patients.  The medications used for each particular 
patient are determined by patient response to therapy and cost of therapy. For full details, see the 
most recent set of GOLD guidelines, from which this material was obtained. 
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